Detail akcie Cytosorbents online

Business Summary: CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Cytosorbents Corp revenues increased 2% to $8.9M. Net loss increased from $1.5M to $5.1M. Revenues reflect All Other segment increase of 5% to $6.1M, United States segment increase of 88% to $118K. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.02 to -$0.08.